Rapid Reliable Testing
Phone: (888)-672-3144
_______________________________________________________________________________________________
Patient: Patel, Nandini
MRN: SHOW13395574 Admit:
FIN: SHOW13395574 Ordering: 1093725822 -Merlin,Mark
DOB/Age/Sex: 3/17/2009 13 years Female
Patient Phone: +15166148175
Infectious Disease
Accession Number Specimen Type Test Collected Date/Time Received Date/Time
SHOW13395574 NP Swab COVID-19 (COVID19) 6/7/2022 10:38 EDT 6/7/2022 23:32 EDT
Test Patient Result Units Reference Range Report Date/Time
SARS COV2 Not Detected f1 *1 [Not Detected] 6/8/2022 08:52 EDT
Result Comments
f1: SARS COV2
Reference Range: NOT DETECTED Test Information The PRL SARS-CoV-2(COVID-19) test is a real-time
reverse transcription polymerase chain reaction (rRT-PCR) test. The SARS-CoV-2 primer and probe set is
designed to amplify and detect RNA from the SARS-CoV-2 in respiratory specimens from patients as
recommended for testing by public health authority guidelines. The assay employs the CDC-designed
primer/probe sequences as included in the SARS-CoV-2 (2019-nCoV) CDC qPCR Probe Assay and listed below.
SARS-CoV-2-specific sequences target two separate regions of the viral nucleocapsid (N) gene. Also included is
an internal control targeting the human RNase P (RP) gene. All three targets are detected in a single assay in
multiplex, each with a unique fluorophore-quencher combination. Limitations: 1. The accuracy of the reported
results are dependent upon correct collection, transport, storage and processing of the sample. 2. Viral detection
depends on the number of viral copies within the processed sample which can be affected by different collection
methods, presence of amplification inhibitors, patient factors (e.g., age, presence of symptoms) and/or the stage
of infection. 3. SARS-CoV-2 may not be detected by this assay if a genetic mutation has occurred in the gene
target region. 4. Negative results do not preclude infection from SARS-CoV-2 and should not be used as the sole
basis for diagnosis, treatment, or other patient management decisions. Negative results must be combined with
clinical observations, patient history, and/or epidemiological information. 5. Detection of SARS-CoV-2 RNA may
not indicate the presence of infectious SARS-CoV-2 or that SARS-CoV-2 is the causative agent of symptoms. 6.
This assay cannot preclude the presence of other viral and/or bacterial pathogens. This test was developed, and
its performance characteristics determined by the Pandemic Response Laboratory (PRL). It has not been cleared
or approved by the U.S. Food and Drug Administration. The test methodology has been validated in-house and
has been reviewed and approved by the Clinical Laboratory Evaluation Program of the New York State
Department of Health. The validation data is available at the Laboratory at the address below. PRL participates in
inter-laboratory testing under the auspices of the College of American Pathologists, in keeping with the Clinical
Laboratory Improvement Amendments of 1988 (CLIA 88).
Performing Locations
*1: This test was performed at:
NY PRL Lab, Medical Director: Dr. Sam Reichberg, M.D. CLIA# 33D2196459, 45-18 Ct Square West, Long Island
City, NY, 11101-
_______________________________________________________________________________________________
LEGEND: @ = Abnormal, C = Critical, L = Low, H = High, <- = Import Action, i = Interp Data, * = Performing Lab
Report Request ID: 6515927 Page 1 of 1 Generated By:
Print Date/Time: 6/8/2022 08:52 EDT
This document contains private and confidential health information protected by state and federal law. If you have received
this document in error or have inquiries, please call the phone number in the header.
